Armed Hunter Killers: Discerning the Role of Adoptive T-Cell Transfer for Glioblastoma
2015; Future Medicine; Volume: 7; Issue: 5 Linguagem: Inglês
10.2217/imt.15.22
ISSN1750-7448
AutoresHeba Samaha, Shahenda El‐Naggar, Nabil Ahmed,
Tópico(s)Virus-based gene therapy research
ResumoImmunotherapyVol. 7, No. 5 CommentaryArmed hunter killers: discerning the role of adoptive T-cell transfer for glioblastomaHeba Samaha, Shahenda El Naggar & Nabil AhmedHeba SamahaAuthor for correspondence: E-mail Address: heba.samaha@57357.orgBasic Research Department Children's Cancer Hospital Egypt (CCHE 57357), 1 Seket el Emam, Sayeda Zeinab, Cairo, Egypt, 11441, Shahenda El NaggarBasic Research Department Children's Cancer Hospital Egypt (CCHE 57357), 1 Seket el Emam, Sayeda Zeinab, Cairo, Egypt, 11441 & Nabil AhmedCenter for Cell & Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital, Houston, TX, USATexas Children's Cancer & Hematology Centers, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USAPublished Online:12 Jun 2015https://doi.org/10.2217/imt.15.22AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInRedditEmail View articleKeywords: adoptive T-cell therapyCARschimeric antigen receptorsGBMglioblastomaimmunotherapyTAAReferences1 Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro. Oncol. 14(Suppl. 5), v1–49 (2012).Crossref, Medline, Google Scholar2 Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 987–996 (2005).Crossref, Medline, Google Scholar3 Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061–1068 (2008).Crossref, Medline, Google Scholar4 Bielamowicz K, Khawja S, Ahmed N. Adoptive cell therapies for glioblastoma. Front. Oncol. 3, 275 (2013).Crossref, Medline, Google Scholar5 Darcy PK, Neeson P, Yong CS, Kershaw MH. Manipulating immune cells for adoptive immunotherapy of cancer. Curr. Opin. Immunol. 27, 46–52 (2014).Crossref, Medline, CAS, Google Scholar6 Hegde M, Bielamowicz KJ, Ahmed N. Novel approaches and mechanisms of immunotherapy for glioblastoma. Discov. Med. 17(93), 145–154 (2014).Medline, Google Scholar7 Eshhar Z. From the mouse cage to human therapy: a personal perspective of the emergence of T-bodies/chimeric antigen receptor T cells. Hum Gene Ther. 25(9), 773–778 (2014).Crossref, Medline, CAS, Google Scholar8 Pegram HJ, Kershaw MH, Darcy PK. Genetic modification of natural killer cells for adoptive cellular immunotherapy. Immunotherapy 1, 623–630 (2009).Link, CAS, Google Scholar9 Altaner C, Altanerova V, Cihova M et al. Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario. Int. J. Cancer 134, 1458–1465 (2014).Crossref, Medline, CAS, Google Scholar10 Stuckey DW, Shah K. Stem cell-based therapies for cancer treatment: separating hope from hype. Nat. Rev. Cancer 14(10), 683–691 (2014).Crossref, Medline, CAS, Google Scholar11 Teng MW, Ritchie DS, Neeson P, Smyth MJ. Biology and clinical observations of regulatory T cells in cancer immunology. Curr. Top. Microbiol. Immunol. 344, 61–95 (2011).Medline, CAS, Google Scholar12 Highfill SL, Cui Y, Giles AJ et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Transl. Med. 6, 237ra67 (2014).Crossref, Medline, Google Scholar13 Albesiano E, Han JE, Lim M. Mechanisms of local immunoresistance in glioma. Neurosurg. Clin. N. Am. 21, 17–29 (2010).Crossref, Medline, Google Scholar14 Bindea G, Mlecnik B, Fridman WH, Pagès F, Galon J. Natural immunity to cancer in humans. Curr. Opin. Immunol. 22, 215–222 (2010).Crossref, Medline, CAS, Google Scholar15 Groopman J. The T-cell army can the body's immune response help treat cancer? New Yorker (23 April 2012).Google Scholar16 Tsuboi K, Saijo K, Ishikawa E et al. Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas. Clin. Cancer Res. 9, 3294–3302 (2003).Medline, Google Scholar17 Politikos I, Boussiotis VA. The role of the thymus in T-cell immune reconstitution after umbilical cord blood transplantation. Blood 124, 3201–3211 (2014).Crossref, Medline, CAS, Google Scholar18 Heslop HE. Safer CARS. Mol Ther. 18, 661–662 (2010).Crossref, Medline, CAS, Google Scholar19 Ghazi A, Ashoori A, Hanley PJ et al. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma. J. Immunother. 35, 159–168 (2012).Crossref, Medline, CAS, Google Scholar20 Schuessler A, Smith C, Beagley L et al. Autologous T cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. Cancer Res. 74(13), 3466–3476 (2014).Crossref, Medline, CAS, Google Scholar21 Ahmed N, Salsman VS, Kew Y et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin. Cancer Res. 16, 474–485 (2010).Crossref, Medline, CAS, Google Scholar22 Goff SL, Johnson LA, Black MA et al. Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion. Cancer Immunol. Immunother. 59, 1551–1560 (2010).Crossref, Medline, CAS, Google Scholar23 Van Loenen MM, de Boer R, Hagedoorn RS et al. Multi-cistronic vector encoding optimized safety switch for adoptive therapy with T-cell receptor-modified T cells. Gene Ther. 20, 861–867 (2013).Crossref, Medline, CAS, Google Scholar24 Shao H, Zhang W, Hu Q, Wu F, Shen H, Huang S. TCR mispairing in genetically modified T cells was detected by fluorescence resonance energy transfer. Mol. Biol. Rep. 37, 3951–3956 (2010).Crossref, Medline, CAS, Google Scholar25 Krebs S, Rodríguez-Cruz TG, Derenzo C, Gottschalk S. Genetically modified T cells to target glioblastoma. Front. Oncol. 3, 322 (2013).Crossref, Medline, Google Scholar26 Pule M, Finney H, Lawson A. Artificial T-cell receptors. Cytotherapy 5, 211–226 (2003).Crossref, Medline, CAS, Google Scholar27 Henderson MA, Yong CS, Duong CP et al. Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor. Immunotherapy 5, 577–590 (2013).Link, CAS, Google Scholar28 Neeson P, Shin A, Tainton KM et al. Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype. Gene Ther. 17, 1105–1116 (2010).Crossref, Medline, CAS, Google Scholar29 Johnson LA et al. Pre-clinical validation of a humanized anti-EGFR variant III chimeric antigen receptor and Phase I trial of CART-EGFRvIII in glioblastoma. J. Immunother. Cancer 2, O1 (2014).Crossref, Medline, Google Scholar30 Krebs S, Chow KK, Yi Z et al. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein-chimeric antigen receptors have anti-glioma activity but alsorecognize interleukin-13Rα1. Cytotherapy 16, 1121–1131 (2014).Crossref, Medline, CAS, Google Scholar31 Chow KK, Naik S, Kakarla S et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol. Ther. 21(3), 629–637 (2012).Crossref, Medline, Google Scholar32 Brown CE et al. Adoptive transfer of IL13R a 2-specific T cells for the treatment of glioblastoma: building on clinical achievements with second-generation CARs. J. Immunother. Cancer 1, P2 (2013).Crossref, Medline, Google Scholar33 Grada Z, Hegde M, Byrd T et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol. Ther. Nucleic Acids 2, e105 (2013).Crossref, Medline, Google Scholar34 Gedeon PC, Choi BD, Hodges TR, Mitchell DA, Bigner DD, Sampson JH. An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. Expert Rev. Clin. Pharmacol. 6, 375–386 (2013).Crossref, Medline, CAS, Google Scholar35 Hoffman LM, Gore L. Blinatumomab, a bi-specific anti-CD19/CD3 BiTE(®) antibody for the treatment of acute lymphoblastic leukemia: perspectives and current pediatric applications. Front. Oncol. 4, 63 (2014).Crossref, Medline, Google Scholar36 Yu F, Wang X, Guo ZS, Bartlett DL, Gottschalk SM, Song XT. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy. Mol. Ther. 22, 102–111 (2014).Crossref, Medline, CAS, Google Scholar37 Neeson P, Paterson Y. Effects of the tumor microenvironment on the efficacy of tumor immunotherapy. Immunol. Invest. 35, 359–394 (2006).Crossref, Medline, CAS, Google Scholar38 Joseph JV, Balasubramaniyan V, Walenkamp A, Kruyt FA. TGF-β as a therapeutic target in high grade gliomas – promises and challenges. Biochem. Pharmacol. 85, 478–485 (2013).Crossref, Medline, CAS, Google Scholar39 Devaud C, John LB, Westwood JA, Darcy PK, Kershaw MH. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology 2, e25961 (2013).Crossref, Medline, Google Scholar40 Tsao CT, Kievit FM, Ravanpay A et al. Thermoreversible poly(ethylene glycol)-g-chitosan hydrogel as a therapeutic T lymphocyte depot for localized glioblastoma immunotherapy. Biomacrmolecules 15(7), 2656–2662 (2014).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetailsCited ByMalignant Spinal Tumors16 July 2023Dendritic cells transduced with glioma-expressed antigen 2 recombinant adenovirus induces specific cytotoxic lymphocyte response and anti-tumor effect in mice31 January 2020 | Journal of Inflammation, Vol. 17, No. 1Novel Immunotherapeutics for Treatment of Glioblastoma: The Last Decade of Research11 January 2019 | Cancer Investigation, Vol. 37, No. 1Spinal cord astrocytomas: progresses in experimental and clinical investigations for developing recovery neurobiology-based novel therapiesExperimental Neurology, Vol. 311 Vol. 7, No. 5 STAY CONNECTED Metrics Downloaded 159 times History Published online 12 June 2015 Published in print June 2015 Information© Future Medicine LtdKeywordsadoptive T-cell therapyCARschimeric antigen receptorsGBMglioblastomaimmunotherapyTAAFinancial & competing interests disclosureThis work was funded by L'Oreal Women in Science Fellowship Award, Science and Technology Development Fund (STDF), AFNCI, Children's Cancer Hospital Foundation (CCHF), the Alliance for Cancer Gene Therapy (ACGT, Inc.), Alex's Lemonade Stand Pediatric Cancer Foundation (ALSF) and by a Stand Up To Cancer St Baldrick's Pediatric Dream Team Translational Research Grant (SU2C-AACR-DT1113). Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research. The Center for Cell and Gene Therapy (CAGT) has research collaboration with Celgene, Inc., to develop CAR based therapeutics that is administered by Baylor College of Medicine. N Ahmed has patent applications in the field of T-cell and gene-modified T-cell therapy for cancer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download
Referência(s)